INT118610

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2004
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 6.88
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (BPHL) cellular amino acid metabolic process (BPHL)
Anatomy Link Frequency
lower urinary tract 1
MCF-7 1
BPHL (Homo sapiens)
Pain Link Frequency Relevance Heat
Neurotransmitter 2 92.12 High High
Buprenorphine 2 89.36 High High
Analgesic 2 88.80 High High
Potency 1 66.08 Quite High
antagonist 30 46.12 Quite Low
Angina 5 22.16 Low Low
depression 25 5.00 Very Low Very Low Very Low
transdermal 15 5.00 Very Low Very Low Very Low
withdrawal 6 5.00 Very Low Very Low Very Low
Onset of action 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 328 100.00 Very High Very High Very High
Lower Urinary Tract Symptoms 151 99.88 Very High Very High Very High
Hematuria 40 99.64 Very High Very High Very High
Overactive Bladder 71 99.56 Very High Very High Very High
Disease 34 97.56 Very High Very High Very High
Apoptosis 8 97.56 Very High Very High Very High
Obstructive Uropathy 1 96.20 Very High Very High Very High
Aging 46 95.72 Very High Very High Very High
Death 8 95.36 Very High Very High Very High
Reprotox - General 1 133 95.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Etiology of BPH
Localization (Etiology) of BPH associated with benign prostatic hypertrophy
1) Confidence 0.57 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.07 Pain Relevance 0.03
While alpha-blockers provide rapid relief in the form of improved flow rate, their effects may not reduce the overall risk of BPH-related complications. 5?
Localization (risk) of BPH associated with benign prostatic hypertrophy
2) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 0.97 Pain Relevance 0.05
Mean MVD was found to be significantly lower in the finasteride group compared to placebo (P < 0.01) leading to the conclusion that finasteride inhibits angiogenic growth factors which contribute to reduced vascularity and decreased BPH-related hematuria, even as early as 2 weeks.
Localization (decreased) of BPH associated with benign prostatic hypertrophy and hematuria
3) Confidence 0.33 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 1.01 Pain Relevance 0
Histological BPH is found in approximately 50% of men aged 51–60 years and in approximately 90% of men aged 81–90 years (Figure 1) (Berry et al 1984).
Localization (found) of BPH associated with benign prostatic hypertrophy
4) Confidence 0.26 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 1.34 Pain Relevance 0
Bph caused the release of fluorescent protein from the mitochondria of MCF-7 cells transfected with the pDsRed2-Mito-vector in a time-dependent manner, suggesting disruption of the mitochondrial membrane.
Localization (release) of Bph in MCF-7 associated with benign prostatic hypertrophy
5) Confidence 0.24 Published 2004 Journal Life Sci. Section Abstract Doc Link 15135650 Disease Relevance 1.06 Pain Relevance 0.25
Finally, although there are no compelling data to suggest that testosterone treatment exacerbates lower urinary tract symptoms (LUTS) or promotes acute urinary retention, severe LUTS, due to BPH, represent a relative contraindication which is no longer applicable after successful treatment of lower urinary tract obstruction.45

Prostate cancer

Localization (represent) of BPH in lower urinary tract associated with benign prostatic hypertrophy, obstructive uropathy, overactive bladder, reprotox - general 1 and lower urinary tract symptoms
6) Confidence 0.08 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2701485 Disease Relevance 1.42 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox